Market Overview

Benzinga's Daily Biotech Pulse: Biogen And Eisai's Alzheimer's Drug Meets End Points In Mid-Stage Trial, Obseva To List Shares On Swiss Exchange

Share:
Benzinga's Daily Biotech Pulse: Biogen And Eisai's Alzheimer's Drug Meets End Points In Mid-Stage Trial, Obseva To List Shares On Swiss Exchange
Related IBB
Benzinga's Daily Biotech Pulse: Novartis Licenses Skin Drug, 2 Stocks To Debut
Benzinga's Daily Biotech Pulse: Novartis Earnings, J&J's HIV Combo Clears FDA Hurdle, Cara To Offer Shares
Rounds Report: Aveo Rallied As Investors Are Optimistic About TIVO-3 Future Development (Seeking Alpha)
Related BIIB
Delivering Alpha 2018: Everything You Need To Know
American Express, Biogen, Huntsman, Take-Two: 'Fast Money' Picks For July 19
Factory Mutual Insurance Co Buys Agilent Technologies Inc, Alexion Pharmaceuticals Inc, Morgan ... (GuruFocus)

Here's a roundup of top developments in the biotech space over the last 24 hours.

Scaling the Peaks

(Stocks hitting 52-week highs on July 5)

  • Arbutus Biopharma Corp (NASDAQ: ABUS)
  • Endocyte, Inc. (NASDAQ: ECYT)
  • Merus NV (NASDAQ: MRUS)
  • Orthopediatrics Corp (NASDAQ: KIDS)(Piper Jaffray raised price target from $24 to $30)
  • Repligen Corporation (NASDAQ: RGEN)

Down In The Dumps

(Stocks hitting 52-week lows on July 3)

Stocks In Focus

Biogen-Eisai's Alzheimer's Drug Meets Predefined End Points In Mid-stage Trial

Biogen Inc (NASDAQ: BIIB) and Eisai announced positive topline results from the Phase 2 study of their BAN2401, which was evaluated in a 856-patient trial for treating early Alzheimer's disease.

BAN2401 is an anti-amyloid beta protofibril antibody.

"The study achieved statistical significance on key predefined endpoints evaluating efficacy at 18 months on slowing progression in Alzheimer's Disease Composite Score (ADCOMS) and on reduction of amyloid accumulated in the brain as measured using amyloid-PET (positron emission tomography)," the companies said.

Obseva To List Shares On Swiss Exchange

Obseva SA (NASDAQ: OBSV) announced its shares will be listed on the SIX Swiss Exchange, effective July 13 under the ticker symbol OBSN. The company shares are already listed on the Nasdaq since Jan. 2017. Obseva also indicated that it will not issue any additional shares related to its Swiss listing.

Posted-In: Biotech News Top Stories Pre-Market Outlook Trading Ideas Best of Benzinga

 

Related Articles (BIIB + ABUS)

View Comments and Join the Discussion!